Obatoclax Mesylate (GX15-070)

Catalog No.S1057

Molecular Weight(MW): 413.49

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Cited by 70 Publications

Cancer Cell, 2019, 36(1):68-83

PubMed: 31257073 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.04.011

PubMed: 31155509 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(6)

PubMed: 30875757 ( click the link to review the publication )

Prostate, 2019, 79(11):1347-1359

PubMed: 31228231 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30563080 ( click the link to review the publication )

Cell Death Discov, 2018, 4:107

PubMed: 30479840 ( click the link to review the publication )

Cell Death Dis, 2018, 92(10)

PubMed: 23640461 ( click the link to review the publication )

Antioxidants (Basel), 2018, 10.3390/antiox7110150

PubMed: 30373097 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):965

PubMed: 30305055 ( click the link to review the publication )

J Clin Invest, 2017, 127(1):153-168

PubMed: 27893461 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3513-3526

PubMed: 28522750 ( click the link to review the publication )

Cancer Res, 2017, 10.1158/0008-5472.CAN-16-3424

PubMed: ( click the link to review the publication )

Genome Med, 2017, 9(1):40

PubMed: 28446242 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):52

PubMed: 28403890 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

FEBS J, 2017, 284(2):222-236

PubMed: 27860276 ( click the link to review the publication )

Antimicrob Agents Chemother, 2017, 61(3)

PubMed: 27993855 ( click the link to review the publication )

Electrophoresis, 2017, 10.1002/elps.201600447

PubMed: 28608427 ( click the link to review the publication )

Nat Commun, 2016, 7:11190

PubMed: 27048913 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(21):5370-5382

PubMed: 27178741 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2016, 8(21):13218-31

PubMed: 27160664 ( click the link to review the publication )

Antiviral Res, 2016, 126:69-80

PubMed: 26738783 ( click the link to review the publication )

Cancer Cell Int, 2016, 16:27

PubMed: 27042160 ( click the link to review the publication )
Int J Oncol, 2016, 49(3):953-60

PubMed: 27572939 ( click the link to review the publication )

Oncotarget, 2016, 7(3):3520-32

PubMed: 26657288 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10839-49

PubMed: 26880588 ( click the link to review the publication )

Oncotarget, 2016, 7(35):56253-56265

PubMed: 27494845 ( click the link to review the publication )

Oncotarget, 2016, 8(36):60060-60079

PubMed: 28947954 ( click the link to review the publication )

Nat Chem Biol, 2015, 10.1038/nchembio.1986

PubMed: 26656090 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.05.008

PubMed: 25979228 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e2014

PubMed: 26658189 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):409-21

PubMed: 25308513 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):409-21

PubMed: ( click the link to review the publication )

Cancer Cell Int, 2015, 15:97

PubMed: 26464561 ( click the link to review the publication )

Int J Oncol, 2015, 46(4):1844-8

PubMed: 25647738 ( click the link to review the publication )

BMC Cancer, 2015, 15:919

PubMed: 26585594 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

Mol Cells, 2015, 38(3):279-84

PubMed: 25666350 ( click the link to review the publication )

Anticancer Drugs, 2015, 26(3):331-42

PubMed: 25521557 ( click the link to review the publication )

Arch Pharm Chem Life Sci, 2015, 348: 1-11

PubMed: 25641608 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):20-8

PubMed: 24534203 ( click the link to review the publication )

Endocr Relat Cancer, 2014, 21(5):755-67

PubMed: 25012986 ( click the link to review the publication )

Oral Oncol, 2014, 50(2):120-7

PubMed: 24216166 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 58(7):3689-96

PubMed: 24752266 ( click the link to review the publication )

Biochem Pharmacol, 2014, 92(1):55-61

PubMed: 25107702 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574 ( click the link to review the publication )

Exp Cell Res, 2014, 322(1):217-25

PubMed: 24355809 ( click the link to review the publication )
Life Sci, 2014, 10.1016/j.lfs.2014.07.006

PubMed: 25066930 ( click the link to review the publication )

Oncol Rep, 2014, 32(6):2789-94

PubMed: 25333301 ( click the link to review the publication )

J Cell Biochem, 2014, 115(9):1624-35

PubMed: 24788582 ( click the link to review the publication )

PLoS One, 2014, 9(9):e106571

PubMed: 25192188 ( click the link to review the publication )

Erasmus University Rotterdam, 2014, 978-94-6259-077-9

PubMed: http://repub.eur.nl/pub/50827/ ( click the link to review the publication )

Int J Cancer, 2013, 133(8):1813-24

PubMed: 23580240 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(4):448-59

PubMed: 23395885 ( click the link to review the publication )

J Immunol, 2013, 190(9):4621-6

PubMed: 23547112 ( click the link to review the publication )

Apoptosis, 2013, 18(10):1163-74

PubMed: 23887890 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2013, 49(4):609-18

PubMed: 23668615 ( click the link to review the publication )

Exp Cell Res, 2013, 319(10):1443-50

PubMed: 23416067 ( click the link to review the publication )

PLoS One, 2013, 8(2):e55982

PubMed: 23418490 ( click the link to review the publication )

Helsinki Metropolia University, 2013, Jens Desloovere

PubMed: ( click the link to review the publication )

Cancer Res, 2012, 72(12):3069-79

PubMed: 22525702 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Cancer Lett, 2012, 339(2):288-97

PubMed: 23200668 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e351

PubMed: 22825469 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e299

PubMed: 22513873 ( click the link to review the publication )

Toxicol Sci, 2012, 128(1):79-91

PubMed: 22491427 ( click the link to review the publication )

Cancer Res, 2011, 71(13):4494-505

PubMed: 21555370 ( click the link to review the publication )

BMC Cancer, 2011, 11:24

PubMed: 21247487 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Features

Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.

Targets

Bcl-2 ^[1]
(Cell-free assay)

0.22 μM(Ki)

In vitro

Obatoclax completely inhibits Bak recovery of Mcl-1 at 5 μM in SK-Mel5 cells and overcomes resistance to ABT-373-induced apoptosis conferred by Mcl-1 in KB/Bcl-2 cells. ^[1] Obatoclax is a BH3 mimetic which binds to a broad spectrum of Bcl-2 family members, including Bcl-2, Bcl-xL, and Mcl-1. Obatoclax uniquely displaces BH3 domains by activation of the pocket of Mcl-1 followed by a triggering of apoptosis mediated by oligomerization of Bak and release of cytochrome c. Obatoclax is sensitive to Bcl-xL in cell lines lacking it or showing low expression. It shows low cytotoxicity to Mcl-1, Bcl-2, and Bcl-xL in all the strongly-expressed cell lines. Obatoclax inhibits multiple myeloma (MM) cell lines (KMS12PE, KMS18, MY5, etc.) with IC50 values ranging from 52 to 1100 nM and the inhibition is umimpaired even in the presence of IL-6 or IGF-1, which are resistance to cytotoxic agents, at a concentration of 150 nM. Obatoclax enhances the antimyeloma activity induced by melphalan, dexamethasone, or bortezomib. ^[2] Obatoclax potentiates TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-mediated apoptosis by unsequestering Bak and Bim from Bcl-2/Bcl-xL or Mcl-1 proteins in PANC-1 and BxPC-3 cells. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
KARPAS-45	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUfBSVRCUUN3ME2wMlAxODB\|MUeg{txO	MmTCV2FPT0WU
SK-MEL-30	MkXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTBwMECwN\|U2KM7:TR?=	MVnTRW5ITVJ?
NALM-6	NUDPPFlYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HEfWlEPTB;MD6wNFA{PTZizszN	MonGV2FPT0WU
KYSE-450	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\ZTWM2OD1yLkCwNFQ3QSEQvF2=	NVnwZY8{W0GQR1XS
BHY	M1q4OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jlTGlEPTB;MD6wNFA3ODFizszN	NX7Wcmc2W0GQR1XS
GR-ST	MkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI\JdYhKSzVyPUCuNFAxPjR6IN88US=>	MXXTRW5ITVJ?
786-0	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUjRc5dQUUN3ME2wMlAxODd5NjFOwG0>	MUPTRW5ITVJ?
C-33-A	NVLRTXB3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXiXnBkUUN3ME2wMlAxODh2ODFOwG0>	NGLEcnZUSU6JRWK=
BHT-101	NHzlemRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NY[3eXllUUN3ME2wMlAxOTB4IN88US=>	MWfTRW5ITVJ?
EB2	NYTiWZRlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGTGem5KSzVyPUCuNFAyOThizszN	Mn3zV2FPT0WU
G-361	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TPfGlEPTB;MD6wNFEzPCEQvF2=	NIHuO21USU6JRWK=
KE-37	M3TU[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUfxSGlWUUN3ME2wMlAxOTJ6IN88US=>	Mni5V2FPT0WU
MHH-PREB-1	NFTjRW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkPLTWM2OD1yLkCwNVQh\|ryP	M1rHcnNCVkeHUh?=
MCF7	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYX6TXpjUUN3ME2wMlAxOTV7IN88US=>	M2OzUXNCVkeHUh?=
LOUCY	NEPJNIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYeyTmxoUUN3ME2wMlAxOTd3IN88US=>	MVnTRW5ITVJ?
EW-7	MmOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MknHTWM2OD1yLkCwNVc2KM7:TR?=	MmrjV2FPT0WU
KYSE-510	NHi5PJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2Xlb2lEPTB;MD6wNFI{OyEQvF2=	MlfHV2FPT0WU
SK-MEL-3	NVj5UZRXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NETXdW5KSzVyPUCuNFAzPjRizszN	MVfTRW5ITVJ?
HAL-01	MoTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnodJpKSzVyPUCuNFAzQTdizszN	NVP4PYxjW0GQR1XS
HCC2998	NFLpc3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTBwMECzN\|Uh\|ryP	MUnTRW5ITVJ?
A375	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXqTWM2OD1yLkCwN\|Uh\|ryP	NHfUT5ZUSU6JRWK=
MZ7-mel	NXvXR5JQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFTWW\|VKSzVyPUCuNFA{QTlizszN	NHniNJBUSU6JRWK=
SH-4	NFfZTGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTBwMEC0NVch\|ryP	NXiycVFHW0GQR1XS
HT-144	MnzoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUPTfm93UUN3ME2wMlAxPDNizszN	NWXE[VB[W0GQR1XS
KYSE-140	NVKxRYs{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;2c49KSzVyPUCuNFA1OzVizszN	MmSxV2FPT0WU
PSN1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1KwNmlEPTB;MD6wNFQ3PyEQvF2=	M3TVfnNCVkeHUh?=
COLO-679	NXz5OGdQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTBwMEC0PVgh\|ryP	NH7JbItUSU6JRWK=
SW620	NXnXTppST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nTemlEPTB;MD6wNFUyOSEQvF2=	MY\TRW5ITVJ?
HGC-27	NUH1TGRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjLfIVKSzVyPUCuNFA2OjRizszN	MYfTRW5ITVJ?
IGROV-1	NYq3UFdET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTBwMEC2JO69VQ>?	MXrTRW5ITVJ?
IGR-1	Mn3tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlf0TWM2OD1yLkCwOlAyKM7:TR?=	MkW4V2FPT0WU
EW-1	NFWzUVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYTJR\|UxRTBwMEC2OVEh\|ryP	MmrwV2FPT0WU
769-P	NFLLZ25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoTpTWM2OD1yLkCwOlc5KM7:TR?=	M1fmfXNCVkeHUh?=
HN	M33yNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIDST2NKSzVyPUCuNFA3PzlizszN	Mmr3V2FPT0WU
SIG-M5	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmS0TWM2OD1yLkCwO\|Eh\|ryP	MmLZV2FPT0WU
IST-MEL1	NVXTVJZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUnJR\|UxRTBwMEC4NVgh\|ryP	MonGV2FPT0WU
ST486	MmLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWjJR\|UxRTBwMEC4NlUh\|ryP	NXG5SlA6W0GQR1XS
ES7	NEfJTHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWPJR\|UxRTBwMEC4OFYh\|ryP	M33LWnNCVkeHUh?=
GAK	M3r3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFe3[JhKSzVyPUCuNFA5PDhizszN	M1PiWHNCVkeHUh?=
BB30-HNC	NIrZUlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rWZWlEPTB;MD6wNFg2QCEQvF2=	NEfDWJRUSU6JRWK=
IPC-298	MkmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjaTG1xUUN3ME2wMlAxQTJ5IN88US=>	M1fse3NCVkeHUh?=
NKM-1	Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTBwMEC5O\|Ih\|ryP	NWLEZoJ6W0GQR1XS
RKO	NHu0PXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnITWM2OD1yLkCxNFQ1KM7:TR?=	MoPnV2FPT0WU
ACN	MkD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1jyS2lEPTB;MD6wNVE{OSEQvF2=	Ml3iV2FPT0WU
SW1417	Mn7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NELMeZlKSzVyPUCuNFEzOjVizszN	NWiyRolYW0GQR1XS
SR	NV;2dI5HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1TifGlEPTB;MD6wNVI{PSEQvF2=	NGq2b\|hUSU6JRWK=
SNG-M	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nCWGlEPTB;MD6wNVMyPyEQvF2=	MmnDV2FPT0WU
CAL-12T	M{Duc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF[4cGdKSzVyPUCuNFE{PDZizszN	MlP6V2FPT0WU
HSC-3	M33vc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTBwMEGzOVUh\|ryP	NYXPTYI5W0GQR1XS
DOHH-2	NWizWHF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTBwMEG0NVIh\|ryP	NUfYcmpEW0GQR1XS
NB69	MmfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTBwMEG1OlUh\|ryP	MmfiV2FPT0WU
LC-2-ad	MknLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\kOlYxUUN3ME2wMlAyPThzIN88US=>	NV;YdHYzW0GQR1XS
RVH-421	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2myOWlEPTB;MD6wNVY4PCEQvF2=	NGWxdYlUSU6JRWK=
TGW	MoHkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fIWWlEPTB;MD6wNVc{QSEQvF2=	NXW4ZYNqW0GQR1XS
HCC1569	NEPRdZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIq5SFNKSzVyPUCuNFE4QTdizszN	MWDTRW5ITVJ?
CAL-85-1	NFLUPZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPPTWM2OD1yLkCxPFMzKM7:TR?=	NFm0VWFUSU6JRWK=
RPMI-8402	MmPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnrZTWM2OD1yLkCxPFU5KM7:TR?=	Mn3PV2FPT0WU
THP-1	NFe5PJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFn6R4dKSzVyPUCuNFE6QThizszN	NX3NfnNKW0GQR1XS
ONS-76	MnfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlnvTWM2OD1yLkCyNFM3KM7:TR?=	NEjGe3ZUSU6JRWK=
A2780	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTBwMEKwO\|kh\|ryP	NGricpBUSU6JRWK=
RPMI-2650	NY\RWlB1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3q2RmlEPTB;MD6wNlI6PiEQvF2=	MmDCV2FPT0WU
MEL-HO	M{DqTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIPIPWNKSzVyPUCuNFI{PDhizszN	Mlz2V2FPT0WU
MC-CAR	MmW3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{XtT2lEPTB;MD6wNlM2PiEQvF2=	NYXDfJVDW0GQR1XS
HSC-2	NWfnZpk4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoT6TWM2OD1yLkCyOFY3KM7:TR?=	NIO1bGJUSU6JRWK=
MEL-JUSO	M2f4NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXjyXG1ZUUN3ME2wMlAzPDd\|IN88US=>	M{\0O3NCVkeHUh?=
CAL-62	NE\TTVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUTJR\|UxRTBwMEK2NFIh\|ryP	M2jPbHNCVkeHUh?=
DMS-273	NGPsPGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnL2TWM2OD1yLkCyPFQ4KM7:TR?=	MlHiV2FPT0WU
S-117	MnjqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX34VoMzUUN3ME2wMlAzQTB4IN88US=>	MYLTRW5ITVJ?
SUP-T1	NHrCc4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIrWZmVKSzVyPUCuNFI6PDlizszN	NXvSUXBJW0GQR1XS
MZ2-MEL	Mk[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWLJR\|UxRTBwMEK5OVkh\|ryP	NUL3Rm9TW0GQR1XS
KYSE-270	NUmyOYZGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFfnO5VKSzVyPUCuNFI6PzZizszN	M{naZXNCVkeHUh?=
CMK	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWntW2xEUUN3ME2wMlA{ODJ\|IN88US=>	NXnqTGFHW0GQR1XS
8505C	NF3GOGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEPQW3dKSzVyPUCuNFMxPCEQvF2=	MVjTRW5ITVJ?
NUGC-3	MnzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYfLco11UUN3ME2wMlA{ODR6IN88US=>	MoTXV2FPT0WU
A101D	MnjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfKTWM2OD1yLkCzNFU2KM7:TR?=	MYjTRW5ITVJ?
G-401	MomwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV7JR\|UxRTBwMEOwPVMh\|ryP	NXzs[VlIW0GQR1XS
OVCAR-8	NF;tVItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlT1TWM2OD1yLkCzNVA4KM7:TR?=	NXHpfXhCW0GQR1XS
IMR-5	MoexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XEWGlEPTB;MD6wN\|I1PCEQvF2=	NWXWcppmW0GQR1XS
DoTc2-4510	NVPkZXE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml60TWM2OD1yLkCzN\|k{KM7:TR?=	NV7aeGp5W0GQR1XS
HOS	NXHXeFZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mlq1TWM2OD1yLkCzOFc{KM7:TR?=	NETvXXNUSU6JRWK=
HEC-1	NFvmN2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnjRpVKSzVyPUCuNFM3QCEQvF2=	NHHWVW9USU6JRWK=
SW756	NELWcXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH7KVnBKSzVyPUCuNFM5OjFizszN	MoLsV2FPT0WU
NCI-H64	NFzIUpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV3JR\|UxRTBwMEO4OFIh\|ryP	NVLzPXlLW0GQR1XS
EW-16	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXnJR\|UxRTBwMEO5NFkh\|ryP	NG\lTGNUSU6JRWK=
CAL-51	MkLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MofJTWM2OD1yLkC0NFA2KM7:TR?=	M1TS[3NCVkeHUh?=
KYSE-150	M3v4Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnqc2pKSzVyPUCuNFQxOTFizszN	MmDSV2FPT0WU
SW1710	NVfuWmZ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIPrOXlKSzVyPUCuNFQxOThizszN	NH\0TmhUSU6JRWK=
HuP-T4	NFn6dW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEW5[mxKSzVyPUCuNFQyOThizszN	NXn6eIZtW0GQR1XS
LB373-MEL-D	Mm[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NF\MeJFKSzVyPUCuNFQzOzJizszN	NWPUS3FXW0GQR1XS
EW-13	MmfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIW2NlBKSzVyPUCuNFQ1ODZizszN	NXP2b5dWW0GQR1XS
HT-29	M4\2TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTBwMES0PUDPxE1?	MXjTRW5ITVJ?
SCC-25	NWiwenBJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\PRphTUUN3ME2wMlA1PDl2IN88US=>	NI[2b\|FUSU6JRWK=
REH	MoX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTBwMES2N\|Uh\|ryP	NVS0d\|FTW0GQR1XS
L-363	NFX0UoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTBwMES2O\|kh\|ryP	M1LJfHNCVkeHUh?=
NCI-H1770	NXO4WYxCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIjIdpZKSzVyPUCuNFQ3QTdizszN	NFj4PHJUSU6JRWK=
CHL-1	M4DTUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYXJR\|UxRTBwMES4OVch\|ryP	NYLrPHgyW0GQR1XS
ES1	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2LHVWlEPTB;MD6wOFg5PSEQvF2=	M4TaPXNCVkeHUh?=
SCC-15	NXPRW\|BsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVfJR\|UxRTBwMES5NFIh\|ryP	MYHTRW5ITVJ?
MRK-nu-1	Mn\uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1;ZS2lEPTB;MD6wOFk{PiEQvF2=	NGnvcVVUSU6JRWK=
PF-382	M1;CTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NES3U2ZKSzVyPUCuNFQ6OzlizszN	MmfWV2FPT0WU
COLO-680N	NEi5bnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPaTWM2OD1yLkC1NFQ4KM7:TR?=	NGPW[IVUSU6JRWK=
LK-2	M1rJSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnH6TWM2OD1yLkC1NFY{KM7:TR?=	NHvLNGtUSU6JRWK=
NCI-H2342	NGfudVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3Hqe2lEPTB;MD6wOVEyPyEQvF2=	MlPwV2FPT0WU
HMV-II	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3z0bmlEPTB;MD6wOVI{QSEQvF2=	NVLBVJc6W0GQR1XS
PC-14	NEDBNYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVTtNYVbUUN3ME2wMlA2OjV{IN88US=>	NFnMTo1USU6JRWK=
COLO-320-HSR	Mn\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml3ZTWM2OD1yLkC1Nlg6KM7:TR?=	MXHTRW5ITVJ?
697	M3XyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVzJR\|UxRTBwMEWzNlMh\|ryP	MY\TRW5ITVJ?
NEC8	NIDTdXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHYeFI1UUN3ME2wMlA2PTlizszN	M3jYOXNCVkeHUh?=
LCLC-97TM1	NH\Fd3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLFXFZkUUN3ME2wMlA2PTl2IN88US=>	M2n5ZXNCVkeHUh?=
Daoy	MoW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnXqTWM2OD1yLkC1OlE3KM7:TR?=	MnT3V2FPT0WU
ETK-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37GTGlEPTB;MD6wOVY4OiEQvF2=	M{DNS3NCVkeHUh?=
A388	NG\rZYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1LU[2lEPTB;MD6wOVY6PSEQvF2=	MWnTRW5ITVJ?
COLO-205	MoTHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{PvS2lEPTB;MD6wOVcyPiEQvF2=	MmLnV2FPT0WU
SK-PN-DW	NULMZ4lOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4q4eWlEPTB;MD6wOVczQSEQvF2=	MVfTRW5ITVJ?
SF268	M{fJNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLITWM2OD1yLkC1O\|U3KM7:TR?=	M3zlOXNCVkeHUh?=
OCI-AML2	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX6zcmtXUUN3ME2wMlA2Pzd5IN88US=>	NUfnZZliW0GQR1XS
GAMG	Mn7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXYTWM2OD1yLkC1PEDPxE1?	MX3TRW5ITVJ?
BCPAP	M3;hPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;BU4RKSzVyPUCuNFU5QTJizszN	Ml;mV2FPT0WU
BC-1	NFrmPZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M13jXmlEPTB;MD6wOlAzOiEQvF2=	M1fQZ3NCVkeHUh?=
IA-LM	MorFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUnrVmhzUUN3ME2wMlA3ODV\|IN88US=>	NVTs[mhLW0GQR1XS
NCI-H1299	NYT4[XNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjjTWM2OD1yLkC2NVMh\|ryP	MYHTRW5ITVJ?
COR-L23	M1S1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFzK[4VKSzVyPUCuNFYyOzRizszN	NFzCNVBUSU6JRWK=
KYSE-180	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mon5TWM2OD1yLkC2NVQzKM7:TR?=	NVXjNYt1W0GQR1XS
LOXIMVI	NHzHclBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHDU4p2UUN3ME2wMlA3OTh6IN88US=>	MkHLV2FPT0WU
BL-41	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjBUmJKSzVyPUCuNFYzOTlizszN	Mn3TV2FPT0WU
BL-70	MmHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnrhTWM2OD1yLkC2N\|AzKM7:TR?=	MofRV2FPT0WU
NOS-1	M{nJfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHznOYdKSzVyPUCuNFY1OTFizszN	NH3Lc3ZUSU6JRWK=
NB13	NWLQSo1sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWW4U4w4UUN3ME2wMlA3PDJzIN88US=>	MXrTRW5ITVJ?
CAL-27	MoW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTBwME[0OlQh\|ryP	NGPhcIZUSU6JRWK=
CA46	M4rQfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TEW2lEPTB;MD6wOlU{PyEQvF2=	M3;VbHNCVkeHUh?=
SW962	NXrNbY9RT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\yfJVnUUN3ME2wMlA3PTZ7IN88US=>	NITUWJVUSU6JRWK=
NCI-H226	MnvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlrWTWM2OD1yLkC2OlMzKM7:TR?=	M3Gxd3NCVkeHUh?=
KYSE-70	NWXne415T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUTMd2UzUUN3ME2wMlA3QTR3IN88US=>	M33MdHNCVkeHUh?=
Daudi	NXrP[W9WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4\kV2lEPTB;MD6wO\|A5OSEQvF2=	MUDTRW5ITVJ?
SW626	NULpRW5GT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3q3b2lEPTB;MD6wO\|IxPCEQvF2=	M2G0ZnNCVkeHUh?=
ESS-1	MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnQS3RDUUN3ME2wMlA4OjR4IN88US=>	NYS1Nmg2W0GQR1XS
YT	NGPIbG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2D4bWlEPTB;MD6wO\|M1PSEQvF2=	MkLqV2FPT0WU
P12-ICHIKAWA	NUHsWYhsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTBwMEezOFkh\|ryP	M1yyTXNCVkeHUh?=
BxPC-3	M122NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUfJR\|UxRTBwMEe0OVgh\|ryP	NUHLVpV4W0GQR1XS
CTV-1	M{jHNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jiOGlEPTB;MD6wO\|UyPyEQvF2=	NIPBTWNUSU6JRWK=
MLMA	NGDKN2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{fqS2lEPTB;MD6wO\|U{PCEQvF2=	NH;PUoZUSU6JRWK=
WSU-NHL	M33ZVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MonUTWM2OD1yLkC3OVU1KM7:TR?=	NIXaT4NUSU6JRWK=
CTB-1	NVTEbopST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVjQd\|JVUUN3ME2wMlA4PTh6IN88US=>	MXrTRW5ITVJ?
MMAC-SF	M2HVcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYfOcm4{UUN3ME2wMlA4PjZ6IN88US=>	MYLTRW5ITVJ?
8-MG-BA	Mlz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEn2V3FKSzVyPUCuNFc5ODFizszN	MknFV2FPT0WU
NCI-H358	M{e1T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1PyO2lEPTB;MD6wO\|g4QSEQvF2=	MVLTRW5ITVJ?
BFTC-905	MkCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjpT25nUUN3ME2wMlA4QTB7IN88US=>	MXXTRW5ITVJ?
NCI-H727	M1nlPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3H5[GlEPTB;MD6wPFA2OyEQvF2=	M1XGbnNCVkeHUh?=
CHP-212	NUDlUVlvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rvfGlEPTB;MD6wPFA6PSEQvF2=	MlPBV2FPT0WU
HOP-62	MmTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULNOllzUUN3ME2wMlA5OjR3IN88US=>	NFi2emlUSU6JRWK=
CESS	MoPaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3uW4VCUUN3ME2wMlA5OjZ7IN88US=>	MnyyV2FPT0WU
HuCCT1	NHPpTlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHZ[oNKSzVyPUCuNFg{OzNizszN	MkDHV2FPT0WU
DEL	NYPVR25HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV;JR\|UxRTBwMEizOFch\|ryP	M3fHR3NCVkeHUh?=
5637	NVfVWG5rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTBwMEizOlch\|ryP	NXWxZZNGW0GQR1XS
RS4-11	MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TIZ2lEPTB;MD6wPFQ6PyEQvF2=	MlnoV2FPT0WU
KURAMOCHI	M4fDTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH;4[W5KSzVyPUCuNFg2ODlizszN	M3TMTnNCVkeHUh?=
A427	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4fQT2lEPTB;MD6wPFUyOiEQvF2=	NUfXeGg4W0GQR1XS
A3-KAW	MmPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFPQeVFKSzVyPUCuNFg2PjZizszN	NXPpWm5{W0GQR1XS
LS-123	NXjXUndPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUXyNXRMUUN3ME2wMlA5PzF7IN88US=>	MUXTRW5ITVJ?
LoVo	NFHI[YZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTBwMEi3NkDPxE1?	M1vTPXNCVkeHUh?=
PA-1	NUnKZ2l{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV34O3luUUN3ME2wMlA5PzZ7IN88US=>	NHHsfm5USU6JRWK=
CP50-MEL-B	M17Ocmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYL6cHQ3UUN3ME2wMlA5Pzl\|IN88US=>	NX;m[Wc3W0GQR1XS
A431	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTBwMEi4NFEh\|ryP	M4X1fnNCVkeHUh?=
HCT-116	NVTxO3ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWKwVXdzUUN3ME2wMlA5QDB{IN88US=>	M3nzdnNCVkeHUh?=
A4-Fuk	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mme2TWM2OD1yLkC4PVQ4KM7:TR?=	NYe3OodWW0GQR1XS
RPMI-6666	NWm3SYxRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jJZmlEPTB;MD6wPFk3PyEQvF2=	MnW5V2FPT0WU
Calu-6	M2j1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\zNnVDUUN3ME2wMlA6ODJ7IN88US=>	MXzTRW5ITVJ?
KMOE-2	NEPwN\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2PxSGlEPTB;MD6wPVA{QSEQvF2=	M1G4[HNCVkeHUh?=
A704	M{\G[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MorzTWM2OD1yLkC5NVUh\|ryP	MkTHV2FPT0WU
HO-1-N-1	M3jSSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXe0[2pZUUN3ME2wMlA6OjR7IN88US=>	NWnEOm5OW0GQR1XS
NCI-H2122	NH7J[oxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYDZdFFqUUN3ME2wMlA6Ozd6IN88US=>	MorDV2FPT0WU
U-698-M	M4e0UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3Xkd2lEPTB;MD6wPVQxQSEQvF2=	MXvTRW5ITVJ?
IST-SL2	NFPNSYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPD[VR3UUN3ME2wMlA6PDZ6IN88US=>	MWPTRW5ITVJ?
TE-10	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MW\JR\|UxRTBwMEm1PFQh\|ryP	MlvNV2FPT0WU
PANC-03-27	M{TiTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTBwMEm2O\|Eh\|ryP	MVvTRW5ITVJ?
KYSE-410	MkfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUPscmd1UUN3ME2wMlA6Pzl5IN88US=>	NH[5OnRUSU6JRWK=
TE-8	NHTBcnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmrmTWM2OD1yLkC5PFg2KM7:TR?=	NIPoNZBUSU6JRWK=
MN-60	NFnJbXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1zYO2lEPTB;MD6wPVg6PyEQvF2=	MXvTRW5ITVJ?
NCI-H460	M4T6emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPKWmE4UUN3ME2wMlExODlizszN	MXLTRW5ITVJ?
LB771-HNC	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{\TTmlEPTB;MD6xNFI2PSEQvF2=	NF71bphUSU6JRWK=
ES4	MoL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIDxUVJKSzVyPUCuNVAzPjRizszN	NELHfZVUSU6JRWK=
HUTU-80	NW\rWoNZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1K4PGlEPTB;MD6xNFM3PSEQvF2=	MlLYV2FPT0WU
647-V	NVfw[G92T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2T6T2lEPTB;MD6xNFQxQCEQvF2=	NH3qSpZUSU6JRWK=
HTC-C3	NHToXlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTBwMUC0N\|Ih\|ryP	NHfMfYJUSU6JRWK=
NTERA-S-cl-D1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1PNSmlEPTB;MD6xNFQ1QCEQvF2=	MlTXV2FPT0WU
A2058	M1zjfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnv4TWM2OD1yLkGwOlU2KM7:TR?=	MXfTRW5ITVJ?
MZ1-PC	Mn7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{LsfWlEPTB;MD6xNFg{KM7:TR?=	NI\YN2ZUSU6JRWK=
J82	NITsXW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTBwMUC4PFQh\|ryP	MUfTRW5ITVJ?
ARH-77	MknwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYjPTHVXUUN3ME2wMlEyKM7:TR?=	MYHTRW5ITVJ?
Ca9-22	MnTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3rVU2lEPTB;MD6xNVEzQCEQvF2=	NWT4RoNGW0GQR1XS
NCI-H1648	NITrXJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmjoTWM2OD1yLkGxNlg3KM7:TR?=	MV3TRW5ITVJ?
MC116	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{O4UGlEPTB;MD6xNVM{PyEQvF2=	MofHV2FPT0WU
EoL-1-cell	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXqTWM2OD1yLkGxOFY4KM7:TR?=	M1m5fXNCVkeHUh?=
PANC-10-05	NXnwb3R[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWniVpFPUUN3ME2wMlEyPDlzIN88US=>	MXzTRW5ITVJ?
SF539	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4nvNWlEPTB;MD6xNVYyPiEQvF2=	MlW2V2FPT0WU
ES8	MnjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFfScHZKSzVyPUCuNVE3OzNizszN	NYG2NXYzW0GQR1XS
NCI-H810	NFLVZlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVXJR\|UxRTBwMUG2OlQh\|ryP	NXHHWVB3W0GQR1XS
J-RT3-T3-5	NFnOS3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXkcoJKSzVyPUCuNVE4PSEQvF2=	NIX1OVVUSU6JRWK=
NY	MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUHJR\|UxRTBwMUG4NVch\|ryP	M4r1VXNCVkeHUh?=
NCI-SNU-1	NHuydG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\6TWM2OD1yLkGyNVQ5KM7:TR?=	MlHEV2FPT0WU
EFM-19	NX\0WlFPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HKV2lEPTB;MD6xNlM4PCEQvF2=	M2ToN3NCVkeHUh?=
HCC1806	M1S3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTBwMUKzPFMh\|ryP	Mlr2V2FPT0WU
HCE-T	NHuwN5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHGTWM2OD1yLkGyOVMyKM7:TR?=	MUTTRW5ITVJ?
HT-1376	NGXjOXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFvsbI9KSzVyPUCuNVI3PjhizszN	MlTyV2FPT0WU
BE-13	NF;pNVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml\vTWM2OD1yLkGyPFY3KM7:TR?=	NUWxW\|V3W0GQR1XS
NCI-H520	M1HqVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HT[WlEPTB;MD6xNlg3PyEQvF2=	Mny1V2FPT0WU
SK-MES-1	NXXoV\|JMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PTXGlEPTB;MD6xNlkyOyEQvF2=	M1HNenNCVkeHUh?=
SNU-423	NYnmfpliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGDTVmNKSzVyPUCuNVI6OTRizszN	Ml\GV2FPT0WU
Ramos-2G6-4C10	NF\IZZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVXFRZRMUUN3ME2wMlEzQTF4IN88US=>	NGTtV5ZUSU6JRWK=
EW-18	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTBwMUOwNlYh\|ryP	MlW5V2FPT0WU
NCI-H2087	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NI\XbXVKSzVyPUCuNVMxOjdizszN	MXjTRW5ITVJ?
COLO-792	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHSOVdKSzVyPUCuNVMyPjVizszN	NW\tcJFNW0GQR1XS
QIMR-WIL	M3vBSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLuTWM2OD1yLkGzNlI{KM7:TR?=	M4rSRXNCVkeHUh?=
ACHN	Ml7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEOzfVNKSzVyPUCuNVMzPDdizszN	M3PXN3NCVkeHUh?=
RPMI-8866	MmnNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTBwMUOyOlEh\|ryP	MXjTRW5ITVJ?
SK-LU-1	M{flXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIW5SWJKSzVyPUCuNVM1PDlizszN	NIO3XVdUSU6JRWK=
SK-UT-1	NE\UNHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnrOTWM2OD1yLkGzOlI5KM7:TR?=	MUfTRW5ITVJ?
MFE-296	NY\HUpF3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\MO2lEPTB;MD6xN\|g3PCEQvF2=	MV;TRW5ITVJ?
RD	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEXLXWFKSzVyPUCuNVM6QTdizszN	NIi1NJBUSU6JRWK=
LS-411N	M4TsPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTBwMUSyPVUh\|ryP	M3jYUHNCVkeHUh?=
NCI-H747	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTBwMUSzJO69VQ>?	MUHTRW5ITVJ?
ES6	MmXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVrJR\|UxRTBwMUSzOkDPxE1?	NIO0S\|hUSU6JRWK=
TE-1	NETubnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NELKS\|hKSzVyPUCuNVQ1ODdizszN	NV7ib2loW0GQR1XS
SJSA-1	NGnQepdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{\yO2lEPTB;MD6xOFcxPyEQvF2=	MVrTRW5ITVJ?
NCI-H1355	Mk[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvWTWM2OD1yLkG1Nlk{KM7:TR?=	MXrTRW5ITVJ?
HEL	M4f1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGHRT2ZKSzVyPUCuNVU1PDdizszN	NGX3N\|hUSU6JRWK=
639-V	MmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DKPGlEPTB;MD6xOVU6PiEQvF2=	MVrTRW5ITVJ?
AN3-CA	NHHCZWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTBwMUW2N\|kh\|ryP	M2rvOHNCVkeHUh?=
SK-MEL-2	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnSwTWM2OD1yLkG1OlY5KM7:TR?=	NHXYPHZUSU6JRWK=
SW872	NGDyUWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DLUWlEPTB;MD6xOlA1OiEQvF2=	M3LIXXNCVkeHUh?=
DU-4475	M2XoPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1TqVGlEPTB;MD6xOlE3OiEQvF2=	MVrTRW5ITVJ?
YKG-1	Mnj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFrDXIdKSzVyPUCuNVYzPzNizszN	NHT5TXRUSU6JRWK=
GT3TKB	M3vSWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoX4TWM2OD1yLkG2Nlg{KM7:TR?=	NX;ReVJyW0GQR1XS
GB-1	NGPDUlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MonQTWM2OD1yLkG2OFI1KM7:TR?=	NV\iVJd6W0GQR1XS
KARPAS-422	MnvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3MV4ptUUN3ME2wMlE3PTd2IN88US=>	MWnTRW5ITVJ?
ATN-1	M2Dv[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2n1WGlEPTB;MD6xOlY2PiEQvF2=	NU\TO5BXW0GQR1XS
HLE	NUS4PHAyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlTYTWM2OD1yLkG2PFc4KM7:TR?=	NVzQUIw4W0GQR1XS
D-542MG	NWjoZldET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkXKTWM2OD1yLkG2PVg3KM7:TR?=	MWTTRW5ITVJ?
EB-3	M2\tXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nB[WlEPTB;MD6xO\|MyKM7:TR?=	M3GwVXNCVkeHUh?=
HCC1143	M{fEPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmDiTWM2OD1yLkG3N\|k3KM7:TR?=	M{fm[3NCVkeHUh?=
DJM-1	M3jWTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2P6b2lEPTB;MD6xO\|Q2OSEQvF2=	NXnq[G1XW0GQR1XS
BT-474	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\OTWM2OD1yLkG3OFg6KM7:TR?=	MnnuV2FPT0WU
BB65-RCC	NWHpSmZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWPJR\|UxRTBwMUe1OFUh\|ryP	MkizV2FPT0WU
NCI-H292	NFXjZXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkjHTWM2OD1yLkG3OlAyKM7:TR?=	NXnNTWJQW0GQR1XS
MKN28	Mn\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTBwMUe2OVMh\|ryP	M4\Me3NCVkeHUh?=
TK10	MkfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEXt[VFKSzVyPUCuNVc4ODJizszN	NHu1dldUSU6JRWK=
TYK-nu	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWPiT2lZUUN3ME2wMlE4QTR7IN88US=>	MnvsV2FPT0WU
8305C	NYfieYlJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jjeWlEPTB;MD6xO\|k4OSEQvF2=	MVHTRW5ITVJ?
MV-4-11	M17ENmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTBwMUe5O\|ch\|ryP	M17xcHNCVkeHUh?=
NCI-H522	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3zTWM2OD1yLkG4NFk1KM7:TR?=	M2T0[nNCVkeHUh?=
Hs-578-T	NUO5[VVqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTBwMUiyPVIh\|ryP	NUjMfWFZW0GQR1XS
LCLC-103H	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkK0TWM2OD1yLkG4OVI4KM7:TR?=	NFHTOWlUSU6JRWK=
MHH-ES-1	M1;hUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIq0T2NKSzVyPUCuNVg3OjlizszN	MmTlV2FPT0WU
NCI-H441	NUjH[25LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYrISYFQUUN3ME2wMlE6OTR6IN88US=>	NUXkPYp3W0GQR1XS
AM-38	NGDac4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2r1R2lEPTB;MD6xPVIzPSEQvF2=	NX3IdVlOW0GQR1XS
SW1783	NXTwWWNyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV62fVF6UUN3ME2wMlE6OzB3IN88US=>	NGXaOWRUSU6JRWK=
SK-HEP-1	M2Xac2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTBwMUm2N\|ch\|ryP	M1\XZ3NCVkeHUh?=
OAW-28	MlnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\TUXpKSzVyPUCuNlAyPzhizszN	NYXlfFd4W0GQR1XS
TE-15	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PYcWlEPTB;MD6yNFI2OiEQvF2=	NIXHfVhUSU6JRWK=
HCE-4	MkD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1r3V2lEPTB;MD6yNFI5PCEQvF2=	MmXTV2FPT0WU
JiyoyeP-2003	NYW3XmZCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTBwMkCzN\|Yh\|ryP	MUPTRW5ITVJ?
OVCAR-4	MnLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoTsTWM2OD1yLkKwOlI5KM7:TR?=	NHz6boNUSU6JRWK=
SNU-449	NUPudodmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3rFbGlEPTB;MD6yNFc6PyEQvF2=	M4XqNHNCVkeHUh?=
SBC-5	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH\OUmNKSzVyPUCuNlEzOTVizszN	MkXHV2FPT0WU
T84	NVu4SWtlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\RTVhFUUN3ME2wMlIyOjR6IN88US=>	MXHTRW5ITVJ?
LP-1	Ml3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1nQPGlEPTB;MD6yNVMxOiEQvF2=	M4Ly[HNCVkeHUh?=
MG-63	M1rrO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvRS4k2UUN3ME2wMlIyOzh{IN88US=>	NX\vdpVXW0GQR1XS
OAW-42	NV7DO3B6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mom4TWM2OD1yLkKxOFc5KM7:TR?=	NX3n[pc4W0GQR1XS
L-540	M4foXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nreWlEPTB;MD6yNVU6QCEQvF2=	NHfJV\|ZUSU6JRWK=
RH-1	NX;qR2lnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LPb2lEPTB;MD6yNlI1OiEQvF2=	MlvpV2FPT0WU
HCT-15	NWfVbmVOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIO0T4JKSzVyPUCuNlI1QDRizszN	M2joTnNCVkeHUh?=
OCUB-M	MnLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVjRe3lUUUN3ME2wMlIzPDh6IN88US=>	M{DlOnNCVkeHUh?=
GP5d	MnfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEDU[plKSzVyPUCuNlI2OjhizszN	MmH6V2FPT0WU
NCI-H2030	NYfPTWNRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2rIN2lEPTB;MD6yNlc{PCEQvF2=	MVnTRW5ITVJ?
ML-2	Mn65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTBwMkK4PFkh\|ryP	M{PGO3NCVkeHUh?=
CAL-39	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zndWlEPTB;MD6yNlk{PiEQvF2=	M3zWVXNCVkeHUh?=
MIA-PaCa-2	M{LFfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fVcmlEPTB;MD6yN\|I5PyEQvF2=	MkKyV2FPT0WU
TE-9	M1i4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn;tTWM2OD1yLkKzN\|Ih\|ryP	NH7FS2ZUSU6JRWK=
LB2518-MEL	NFztVZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTBwMkOzO\|Ih\|ryP	NGXSeXRUSU6JRWK=
DB	MmD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\JWVNOUUN3ME2wMlI{PDN6IN88US=>	NU\VXWZHW0GQR1XS
NCI-H596	M{\lWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTBwMkO1O\|Eh\|ryP	Mo[2V2FPT0WU
SW1990	NFvGSW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF:5eIpKSzVyPUCuNlM6PDZizszN	MWrTRW5ITVJ?
P30-OHK	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVvJR\|UxRTBwMkSwOUDPxE1?	Mk\4V2FPT0WU
ALL-PO	NW\vbW5ET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTBwMkSxOlkh\|ryP	NUjxdHZPW0GQR1XS
Saos-2	NF7FdIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFr6bo1KSzVyPUCuNlQ2PzFizszN	M2D2c3NCVkeHUh?=
MFH-ino	NU\GOIppT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1uxXWlEPTB;MD6yOFY6OiEQvF2=	NF3hOmtUSU6JRWK=
OE33	M3HBbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlXCTWM2OD1yLkK1NVEh\|ryP	MmnOV2FPT0WU
Calu-3	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVzJR\|UxRTBwMkWyPVch\|ryP	MUPTRW5ITVJ?
HT	M4LVfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlPSTWM2OD1yLkK1OlIyKM7:TR?=	MorFV2FPT0WU
LXF-289	M2TnU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUj1NndSUUN3ME2wMlI2QTh2IN88US=>	MnntV2FPT0WU
KGN	M1G3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX7vcFE6UUN3ME2wMlI3ODh7IN88US=>	MmK5V2FPT0WU
NCI-H1417	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTBwMk[1NlQh\|ryP	Mm\6V2FPT0WU
SF126	NVjTT2xMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTBwMkezNFIh\|ryP	NHXHT2JUSU6JRWK=
SAS	NWL1SYp{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnP2TWM2OD1yLkK3N\|A5KM7:TR?=	NX\DOW1SW0GQR1XS
22RV1	NYXHWG5QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUTBO3BHUUN3ME2wMlI4Ozd6IN88US=>	NHT4b2xUSU6JRWK=
GI-1	NWXqRppnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4TWc2lEPTB;MD6yO\|Q5PyEQvF2=	MV\TRW5ITVJ?
ES3	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYHlbZFrUUN3ME2wMlI4PzZ\|IN88US=>	M{POVHNCVkeHUh?=
NB1	NViwcotnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUPQRmcxUUN3ME2wMlI4QDd4IN88US=>	MX\TRW5ITVJ?
NCI-H650	MmfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTBwMkizNFIh\|ryP	NFvxOI5USU6JRWK=
IST-MES1	NInVR\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGO3UY9KSzVyPUCuNlg2PTRizszN	M3PaN3NCVkeHUh?=
UM-UC-3	MkTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIT2So1KSzVyPUCuNlkyPCEQvF2=	M{D2SXNCVkeHUh?=
CAL-120	M4jRT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2\2TWlEPTB;MD6yPVY{OSEQvF2=	MnTqV2FPT0WU
UACC-62	MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmHnTWM2OD1yLkOwNlQyKM7:TR?=	MWjTRW5ITVJ?
TE-11	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTBwM{CyOFkh\|ryP	MWXTRW5ITVJ?
MKN1	NHPMe4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnW1TWM2OD1yLkOwN\|Yh\|ryP	NFLPNG1USU6JRWK=
KS-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3v0SGlEPTB;MD6zNFUzPiEQvF2=	NWDmcmJQW0GQR1XS
GCIY	MlTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTBwM{GwNFIh\|ryP	NIDpbIFUSU6JRWK=
OVCAR-5	M{myNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVrJR\|UxRTBwM{GxNFYh\|ryP	NFLLU5ZUSU6JRWK=
U-266	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13FVWlEPTB;MD6zNVE1PyEQvF2=	M4nrPHNCVkeHUh?=
Calu-1	Mn3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHfx[GZKSzVyPUCuN\|EzQDlizszN	MVTTRW5ITVJ?
SK-LMS-1	MlPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjVW4V{UUN3ME2wMlMyPDJ7IN88US=>	MnOzV2FPT0WU
COLO-741	NF\icG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlvjTWM2OD1yLkOxOlE1KM7:TR?=	NWLCXnh{W0GQR1XS
RPMI-8226	M4HhNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTBwM{G2OFEh\|ryP	NVyw[45uW0GQR1XS
KM12	NV\QZYhuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\aTWM2OD1yLkOxPFMh\|ryP	M2TRUXNCVkeHUh?=
NMC-G1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M37wPGlEPTB;MD6zNVg3KM7:TR?=	MVHTRW5ITVJ?
SJRH30	MlPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVT1[GQxUUN3ME2wMlMzODV{IN88US=>	M4HuWHNCVkeHUh?=
COR-L105	NVP4OGdxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHHaW3RKSzVyPUCuN\|IzOThizszN	M1u2UXNCVkeHUh?=
IM-9	NHTEVpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHns[mRKSzVyPUCuN\|MxOjFizszN	NVL6bWl{W0GQR1XS
TE-12	M1rCUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXTVWZGUUN3ME2wMlM{OzF5IN88US=>	NVvLfW8zW0GQR1XS
KG-1	NXf0d3J{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Moe4TWM2OD1yLkOzOFMzKM7:TR?=	NUnGVmFPW0GQR1XS
U251	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTBwM{O0OVYh\|ryP	M2TFT3NCVkeHUh?=
EFO-27	M2j4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MojETWM2OD1yLkOzPVUyKM7:TR?=	M1jMRXNCVkeHUh?=
EW-24	MonMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTBwM{O5PFQh\|ryP	M{fr[XNCVkeHUh?=
SF295	NGnYVmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV7JR\|UxRTBwM{O5PVkh\|ryP	NIL0OGpUSU6JRWK=
MC-IXC	MmTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnPjTWM2OD1yLkO0OUDPxE1?	MmG0V2FPT0WU
NCI-H2405	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1\wbWlEPTB;MD6zOFc{OiEQvF2=	NEDYOmRUSU6JRWK=
NCI-H2009	NWPOeo1mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTBwM{S3N\|kh\|ryP	MWrTRW5ITVJ?
LB1047-RCC	NHLHcHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkXSTWM2OD1yLkO1PFE2KM7:TR?=	M1T0dHNCVkeHUh?=
KNS-81-FD	NV3sZ\|ZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEH1NnRKSzVyPUCuN\|Y3PjdizszN	M2rMO3NCVkeHUh?=
HOP-92	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLHNmhKSzVyPUCuN\|Y5OyEQvF2=	MoX4V2FPT0WU
L-428	Mn3kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUHnXXV2UUN3ME2wMlM4ODF4IN88US=>	M3rGSnNCVkeHUh?=
C3A	NGLGe5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnThTWM2OD1yLkO3N\|c6KM7:TR?=	NFvMcJZUSU6JRWK=
NCI-H1792	NVfQUmo1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYnrcoJ2UUN3ME2wMlM4PjV3IN88US=>	MkXjV2FPT0WU
HuH-7	MmLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\CU2NbUUN3ME2wMlM4QTFizszN	M{jsbXNCVkeHUh?=
AGS	NVzqUpNjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2H1WGlEPTB;MD6zPFY{QCEQvF2=	Mke2V2FPT0WU
HT-1197	NWK2UIlKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1Oz[2lEPTB;MD6zPVQ3KM7:TR?=	M{X2bXNCVkeHUh?=
CGTH-W-1	NE\XVmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3XFbmlEPTB;MD6zPVkyOyEQvF2=	NYntR3l5W0GQR1XS
KNS-42	NGW4OINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTBwNECwOFUh\|ryP	M17CU3NCVkeHUh?=
HuO-3N1	M3zSb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkC2TWM2OD1yLkSwNFU2KM7:TR?=	MoTHV2FPT0WU
VMRC-RCZ	NHjnSnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXMVFI1UUN3ME2wMlQxOzB\|IN88US=>	NXPhVJNDW0GQR1XS
SW954	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTBwNECzN\|Uh\|ryP	NGKy[FNUSU6JRWK=
MES-SA	M{[wOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUnJR\|UxRTBwNEC1NFUh\|ryP	MkTSV2FPT0WU
Ca-Ski	NGjsR4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PBWGlEPTB;MD60NFUzPCEQvF2=	M2PKfXNCVkeHUh?=
SW13	MlnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX\BNHh[UUN3ME2wMlQxPjJ4IN88US=>	MkXRV2FPT0WU
NCI-H1437	NUjGblF6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\sTWM2OD1yLkSwPFA2KM7:TR?=	NE\UUVFUSU6JRWK=
U-118-MG	Mmm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;CSI1VUUN3ME2wMlQxQTB2IN88US=>	NV24PFlWW0GQR1XS
NCI-H1734	NFrteGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MormTWM2OD1yLkSyNFE{KM7:TR?=	NIfFdHlUSU6JRWK=
HDLM-2	NUPiXYJVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTBwNEKwN\|Mh\|ryP	NIrQXopUSU6JRWK=
AU565	NFLsRXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYnxeIlXUUN3ME2wMlQzPDZ6IN88US=>	Mn:yV2FPT0WU
FADU	M1Hk[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTBwNEK2OFkh\|ryP	NFzPPHpUSU6JRWK=
OS-RC-2	NF7WV5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjqOm92UUN3ME2wMlQ{ODh\|IN88US=>	NVPSUFY5W0GQR1XS
CAMA-1	M{PSPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlLUTWM2OD1yLkSzOlI3KM7:TR?=	M2XsUnNCVkeHUh?=
MONO-MAC-6	M3LQc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NITsXZBKSzVyPUCuOFM5PDlizszN	MojkV2FPT0WU
LB831-BLC	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{KzR2lEPTB;MD60OFM4OSEQvF2=	MWrTRW5ITVJ?
SW982	MkDvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPNN5BKSzVyPUCuOFQ2OjhizszN	M3zsNnNCVkeHUh?=
SCC-3	NVr4PXpNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTBwNES1O\|kh\|ryP	MorUV2FPT0WU
C32	NHy2XXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGez[YhKSzVyPUCuOFUzOjlizszN	MYXTRW5ITVJ?
BFTC-909	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmTDTWM2OD1yLkS1Nlk6KM7:TR?=	M13PcnNCVkeHUh?=
MEG-01	M2rnPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnXZTWM2OD1yLkS1N\|c{KM7:TR?=	NU\Zdpd3W0GQR1XS
M14	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTBwNEW5O\|kh\|ryP	Moj6V2FPT0WU
MPP-89	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVKyNmw6UUN3ME2wMlQ3OjV4IN88US=>	NUm3VlRJW0GQR1XS
HCC1937	NWHhb5NnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3ZTWM2OD1yLkS2N\|g1KM7:TR?=	MYnTRW5ITVJ?
SW837	MmXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVTwWJFJUUN3ME2wMlQ3PzJ{IN88US=>	MU\TRW5ITVJ?
DU-145	MmLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWDabIlKUUN3ME2wMlQ3PzJ7IN88US=>	MULTRW5ITVJ?
LB996-RCC	NWewXGNxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWPSbYt7UUN3ME2wMlQ4ODV2IN88US=>	NHi1dWdUSU6JRWK=
C8166	NEX4b2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PzN2lEPTB;MD60O\|Qh\|ryP	MUTTRW5ITVJ?
MOLT-4	NGL1NVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYTJR\|UxRTBwNEe3N\|Qh\|ryP	NXTYZ415W0GQR1XS
DMS-53	M4roe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF:yRVFKSzVyPUCuOFc5ODlizszN	MoC3V2FPT0WU
TE-5	M2jvdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3:1dGlEPTB;MD60PFMxPSEQvF2=	NF\rcoNUSU6JRWK=
KYSE-520	M32xOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYrJR\|UxRTBwNEizOFMh\|ryP	NH\uVGhUSU6JRWK=
Detroit562	NX3ue\|d{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXPj[XlkUUN3ME2wMlQ5QDZizszN	NFHHbVBUSU6JRWK=
SIMA	MnrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoTNTWM2OD1yLkS5OFE4KM7:TR?=	MXTTRW5ITVJ?
NCI-H1651	NFfFXXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYfkZVVJUUN3ME2wMlQ6PjdizszN	M1;6SnNCVkeHUh?=
HCC1599	M1TOOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2i2T2lEPTB;MD60PVk2PSEQvF2=	MmjSV2FPT0WU
ABC-1	MmXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnHmTWM2OD1yLkWwOFk3KM7:TR?=	MlTWV2FPT0WU
CAL-33	NVvieJNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLmb4lMUUN3ME2wMlUxQDR2IN88US=>	MkHlV2FPT0WU
OPM-2	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M171PGlEPTB;MD61NFk{PyEQvF2=	Mn;sV2FPT0WU
RPMI-7951	M2TqOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrXNHdKSzVyPUCuOVA6PTdizszN	NHPjNZlUSU6JRWK=
HT-1080	NXThTYY6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\MZ\|NKSzVyPUCuOVEyOTlizszN	M3LUWHNCVkeHUh?=
LC4-1	MkXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTBwNUG0NFMh\|ryP	Ml7KV2FPT0WU
OVCAR-3	MlTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\KZ2lEPTB;MD61NVU4KM7:TR?=	NU\ZZ216W0GQR1XS
CAPAN-1	NEnkWWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3zQSGlEPTB;MD61NlI5QCEQvF2=	NF\BR5FUSU6JRWK=
SK-OV-3	NXTGcFlwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlX0TWM2OD1yLkWyOFM1KM7:TR?=	MmTaV2FPT0WU
HuP-T3	M3vBZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfyR5FbUUN3ME2wMlUzQDJ5IN88US=>	M2O2[3NCVkeHUh?=
NCI-H838	M2C4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHWTWM2OD1yLkWyPFQ6KM7:TR?=	NIj6NphUSU6JRWK=
K5	NIrXW\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTBwNUOyNFEh\|ryP	NVryZmZzW0GQR1XS
CAL-72	NEDCS3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIG4UZRKSzVyPUCuOVM{QDdizszN	MkXEV2FPT0WU
NH-12	M1LSeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHzV3BEUUN3ME2wMlU{QTV7IN88US=>	NULRS\|FSW0GQR1XS
SNB75	MmrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYjJR\|UxRTBwNUW3N{DPxE1?	NIn6b\|lUSU6JRWK=
BPH-1	NHzXfI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\KfnF3UUN3ME2wMlU3OzR2IN88US=>	NX3IT5hHW0GQR1XS
NOMO-1	M4LBdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLBNIlkUUN3ME2wMlU3Ozd{IN88US=>	NFTYbZhUSU6JRWK=
G-402	NW\XdIFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnPTWM2OD1yLkW2OFk6KM7:TR?=	MmfUV2FPT0WU
NCI-H2052	NULhT4JKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NInxXnVKSzVyPUCuOVY4PDFizszN	MYTTRW5ITVJ?
RCM-1	NGTxb3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NELydYJKSzVyPUCuOVcyPjZizszN	M3H6fXNCVkeHUh?=
COR-L279	M3zDTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2fyTmlEPTB;MD61O\|E5PSEQvF2=	M3npd3NCVkeHUh?=
A253	NEXYcWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPEeFlkUUN3ME2wMlU4PTJ3IN88US=>	MlrpV2FPT0WU
SK-MM-2	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH[5WXZKSzVyPUCuOVc3PzlizszN	NYC1boxoW0GQR1XS
NCI-H1703	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH35bFBKSzVyPUCuOVk1OjdizszN	NWPrdY9zW0GQR1XS
UACC-257	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn\ETWM2OD1yLkW5OFg4KM7:TR?=	NFXzU2tUSU6JRWK=
KALS-1	MlewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NI[5d2FKSzVyPUCuOlAxOTFizszN	MWnTRW5ITVJ?
ES5	M{XkXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkfITWM2OD1yLk[wOFgh\|ryP	MkPsV2FPT0WU
MHH-CALL-2	NGHleYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWjtSGZ7UUN3ME2wMlYxQDh6IN88US=>	NFG4bWdUSU6JRWK=
ChaGo-K-1	M2radWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnflTWM2OD1yLk[xNlI6KM7:TR?=	NXzYc4xuW0GQR1XS
TGBC1TKB	NXewNGNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HJcWlEPTB;MD62NVk5KM7:TR?=	NX;kNG5CW0GQR1XS
KU-19-19	M1;nT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3nlT2lEPTB;MD62OFU5PiEQvF2=	NIO5TohUSU6JRWK=
COLO-684	NHv2[4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWDJR\|UxRTBwNkW2NVEh\|ryP	M4LrRnNCVkeHUh?=
LS-1034	MljkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTBwNkW4NVkh\|ryP	Mo\hV2FPT0WU
RT-112	NVLPRVd2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWP1bG5WUUN3ME2wMlY3PTh5IN88US=>	NVvRcnRuW0GQR1XS
Capan-2	M1jTZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2HXV2lEPTB;MD62OlYzOiEQvF2=	NFXxUXdUSU6JRWK=
HSC-4	NV\pd\|VtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHr1W\|VKSzVyPUCuOlY3QThizszN	MVTTRW5ITVJ?
COLO-824	NX34U5c4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\POmUyUUN3ME2wMlY4QDJ\|IN88US=>	NY\NN\|dyW0GQR1XS
NCI-H2170	MmfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmHETWM2OD1yLk[4NlU5KM7:TR?=	M{XqOXNCVkeHUh?=
GDM-1	Mo[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTBwNki0PVQh\|ryP	M3G0S3NCVkeHUh?=
KP-4	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mkj6TWM2OD1yLk[5OVc{KM7:TR?=	M2\qW3NCVkeHUh?=
VA-ES-BJ	NUnmVnhkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3Pnd2lEPTB;MD62PVk5PiEQvF2=	NHvTeWRUSU6JRWK=
KM-H2	NWKzRWo6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGnOTnRKSzVyPUCuO\|AxQTFizszN	M2XlNHNCVkeHUh?=
HH	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3GTWM2OD1yLkewOlYzKM7:TR?=	MoruV2FPT0WU
DK-MG	M3fu[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3xT2hiUUN3ME2wMlcyODF4IN88US=>	NUK0flN1W0GQR1XS
VM-CUB-1	MkLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGTscHRKSzVyPUCuO\|EzPTlizszN	NHXFVXVUSU6JRWK=
COLO-829	MlrOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2L2b2lEPTB;MD63NVk5PSEQvF2=	M4q2WXNCVkeHUh?=
OMC-1	MmrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIXmbWZKSzVyPUCuO\|IyODRizszN	NHy1UWJUSU6JRWK=
NB12	NEiyPINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoTXTWM2OD1yLkeyOVA1KM7:TR?=	MY\TRW5ITVJ?
NCI-H28	NWe3cXpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlW3TWM2OD1yLke0NFg{KM7:TR?=	MkW3V2FPT0WU
A673	NIjyWWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUnPb3hNUUN3ME2wMlc2OTd5IN88US=>	NXPRV2FEW0GQR1XS
LB2241-RCC	NGrkb4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYn6U2lzUUN3ME2wMlc3ODh5IN88US=>	M1vpSnNCVkeHUh?=
CCRF-CEM	NHfNUlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HId2lEPTB;MD63O\|A2OiEQvF2=	NV[3emxxW0GQR1XS
NCI-H510A	M2jLVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYWwc3YxUUN3ME2wMlc4OTh4IN88US=>	M1TK[HNCVkeHUh?=
SW48	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml62TWM2OD1yLke3N\|M{KM7:TR?=	M{S4N3NCVkeHUh?=
NCI-H2081	NF;hZotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHDTWM2OD1yLke4NVQ4KM7:TR?=	MYPTRW5ITVJ?
RMG-I	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVvBN3lYUUN3ME2wMlc5OjF{IN88US=>	NHjUO\|RUSU6JRWK=
LU-99A	NUjoSXVNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLXNZljUUN3ME2wMlc5PDF\|IN88US=>	MUPTRW5ITVJ?
KP-N-YS	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXjJR\|UxRTBwN{i5NlEh\|ryP	M2DRcnNCVkeHUh?=
MDA-MB-231	NV\EbXVQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGj4XXhKSzVyPUCuPFAyOzFizszN	M2jLdXNCVkeHUh?=
U031	NHnIbGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkjITWM2OD1yLkixOFI{KM7:TR?=	MkDTV2FPT0WU
EVSA-T	NXHsUZNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\pTWM2OD1yLkixOlczKM7:TR?=	MXvTRW5ITVJ?
MDA-MB-157	MlriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHXPFlKSzVyPUCuPFIzPzFizszN	NEPGfXVUSU6JRWK=
EHEB	NXTjbmRRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2L2XGlEPTB;MD64NlI4PiEQvF2=	MnPwV2FPT0WU
KINGS-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoX6TWM2OD1yLkiyOVU2KM7:TR?=	M2WxOnNCVkeHUh?=
23132-87	NVvlcI1VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTBwOEK4OFMh\|ryP	MmT6V2FPT0WU
EFO-21	M2jqZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{XuXGlEPTB;MD64OFA5QSEQvF2=	MYrTRW5ITVJ?
DOK	M1L2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljyTWM2OD1yLki0PEDPxE1?	MU\TRW5ITVJ?
NCI-H2171	Mnr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1nYW2lEPTB;MD64OFk3KM7:TR?=	Mon6V2FPT0WU
NCI-SNU-5	NYn4[o5nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX7JR\|UxRTBwOEW1O{DPxE1?	NILBNXlUSU6JRWK=
SK-N-DZ	MkTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fhUGlEPTB;MD64OVk1OyEQvF2=	M3vtOHNCVkeHUh?=
SNU-C2B	NX7DNYdyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIW1WVJKSzVyPUCuPFY5ODFizszN	M1nXWHNCVkeHUh?=
CP66-MEL	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{HRZmlEPTB;MD64O\|EyKM7:TR?=	MXHTRW5ITVJ?
SN12C	Ml3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUf0THh3UUN3ME2wMlg5PjN5IN88US=>	MWrTRW5ITVJ?
A172	NGrMXpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUXZO3R4UUN3ME2wMlg5Pjl6IN88US=>	NWr2fJBiW0GQR1XS
NCI-H2347	M13CV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFr0cHNKSzVyPUCuPFg4PTNizszN	MVPTRW5ITVJ?
NCI-H2228	NIP2[5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYTKSJhZUUN3ME2wMlg6OzN7IN88US=>	NVzCdIljW0GQR1XS
SNU-387	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFP6NVhKSzVyPUCuPVAzPjRizszN	M2m5d3NCVkeHUh?=
SK-MEL-24	M3jYcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV3HZW9pUUN3ME2wMlkyOzR2IN88US=>	M2LOe3NCVkeHUh?=
MDA-MB-468	NH\hT3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHX1ZlJKSzVyPUCuPVE4OyEQvF2=	M4DB[3NCVkeHUh?=
NCI-H1694	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlH1TWM2OD1yLkmxPFc3KM7:TR?=	MULTRW5ITVJ?
CCF-STTG1	NYWyS5VKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPrWYNKSzVyPUCuPVI3OzdizszN	M4j4W3NCVkeHUh?=
K052	M2rUVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWDDT3VOUUN3ME2wMlk1ODR5IN88US=>	MV3TRW5ITVJ?
NCI-H446	NYXDXmVvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jvZ2lEPTB;MD65OVAyKM7:TR?=	MXXTRW5ITVJ?
MFE-280	MkLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmqxTWM2OD1yLkm2NlkyKM7:TR?=	M1HlWXNCVkeHUh?=
KU812	MlrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFzFd4RKSzVyPUCuPVk{QDlizszN	MXvTRW5ITVJ?
MDA-MB-361	MnjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\G[Wd4UUN3ME2wMlk6Pzd5IN88US=>	NVS1b5MxW0GQR1XS
Raji	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTFwMEKyOlch\|ryP	MVLTRW5ITVJ?
TE-6	M3ToTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmPCTWM2OD1zLkCzOVY3KM7:TR?=	NXHCR\|BSW0GQR1XS
CAL-148	MlziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXnJR\|UxRTFwMES0OFMh\|ryP	NYjxUG5bW0GQR1XS
NCI-H1963	NXSzXZR3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUD0VWJ4UUN3ME2xMlA1PTV\|IN88US=>	NUe1cGlOW0GQR1XS
SK-N-AS	M1m2cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVi2WGlFUUN3ME2xMlA1Pjh3IN88US=>	NV32VHFMW0GQR1XS
RERF-LC-MS	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zIb2lEPTB;MT6wOlM1QSEQvF2=	NXnPbIdQW0GQR1XS
BEN	M37zR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NI[0WIZKSzVyPUGuNFcyOzdizszN	NH35e2tUSU6JRWK=
CAS-1	NHLic5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTFwMEmxNlMh\|ryP	MV7TRW5ITVJ?
SW780	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYfJR\|UxRTFwMEmxPFEh\|ryP	NFrt[oRUSU6JRWK=
LU-65	NI\qUnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXFO5hKSzVyPUGuNFk1OSEQvF2=	MljSV2FPT0WU
D-283MED	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYDDfZRQUUN3ME2xMlEzOjd{IN88US=>	NXexdJptW0GQR1XS
HCC2157	NIHzUY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlzkTWM2OD1zLkGzOlQzKM7:TR?=	NV7hfJNFW0GQR1XS
RCC10RGB	M3TROWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUDJR\|UxRTFwMUSwNFYh\|ryP	NEHx[lhUSU6JRWK=
PLC-PRF-5	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYHJR\|UxRTFwMUWyNlkh\|ryP	Ml[wV2FPT0WU
H4	MmT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjOS5VPUUN3ME2xMlE2PDN7IN88US=>	M1LrZnNCVkeHUh?=
TUR	NWDrTJJKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXrJR\|UxRTFwMUW3OVIh\|ryP	MWHTRW5ITVJ?
NCI-H2141	NFn1THZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYPLRpJYUUN3ME2xMlE5QTR4IN88US=>	M1nGPHNCVkeHUh?=
PFSK-1	NEDjdIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVL4S2ZUUUN3ME2xMlIxPTN{IN88US=>	Mln4V2FPT0WU
SK-MEL-28	NGrBRXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnfLTWM2OD1zLkKzNlIyKM7:TR?=	MYPTRW5ITVJ?
SCC-9	NHnlT21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUHJR\|UxRTFwMkO2OlUh\|ryP	NVjsOZdpW0GQR1XS
T47D	MnHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFq2SGZKSzVyPUGuNlM3QTZizszN	NUDweZV2W0GQR1XS
TCCSUP	NYHQ[nVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1qzXmlEPTB;MT6yOVAzQSEQvF2=	NGG4TWRUSU6JRWK=
SU-DHL-1	NH20TppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIjUUWJKSzVyPUGuNlUyOThizszN	MlPUV2FPT0WU
HL-60	NHTtZldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHXKN41KSzVyPUGuNlU2QDhizszN	M3jrNnNCVkeHUh?=
NCI-H1436	NELtVZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWLJR\|UxRTFwMk[xOFkh\|ryP	M4LZbXNCVkeHUh?=
DMS-114	M2Sz[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkDWTWM2OD1zLkK2OlMzKM7:TR?=	M3zHOXNCVkeHUh?=
BOKU	M4\xV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXzJR\|UxRTFwMkiwPVUh\|ryP	NEXEcoxUSU6JRWK=
MS-1	M3zxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTFwMkmwOlkh\|ryP	NH\EflRUSU6JRWK=
NCI-H661	MonqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYDJR\|UxRTFwM{C0O\|gh\|ryP	NEDQPZVUSU6JRWK=
HT-3	NX3XcHBET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUGxTHV2UUN3ME2xMlMxPTJ7IN88US=>	NGXj[ZFUSU6JRWK=
CAL-54	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{PqVmlEPTB;MT6zNFczPSEQvF2=	NHHqZpZUSU6JRWK=
SW1463	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MU\JR\|UxRTFwM{G4O\|Ih\|ryP	MlvSV2FPT0WU
COLO-668	MnTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTFwM{OwOVYh\|ryP	NELFWmlUSU6JRWK=
PANC-08-13	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HsPGlEPTB;MT6zN\|gxOyEQvF2=	MXXTRW5ITVJ?
BB49-HNC	NFGzb4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTFwM{SwNUDPxE1?	MoLwV2FPT0WU
M059J	NYHHSlF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG\ub2RKSzVyPUGuN\|U5OzJizszN	NIfUWYZUSU6JRWK=
NCCIT	Mn\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHzdIJKSzVyPUGuN\|c6QDhizszN	M3nNZXNCVkeHUh?=
LN-405	NXTFd5lyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1TIPWlEPTB;MT6zPVI3PCEQvF2=	Mk\JV2FPT0WU
UMC-11	NHvjRmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFrnZ21KSzVyPUGuN\|k6QTZizszN	MkXFV2FPT0WU
NB5	M{C3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XwZ2lEPTB;MT60NVIzPyEQvF2=	MUfTRW5ITVJ?
TE-441-T	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXn6dHAxUUN3ME2xMlQzQDF5IN88US=>	Mn;jV2FPT0WU
ME-180	M3G3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1jlcWlEPTB;MT60OFM6OiEQvF2=	MX7TRW5ITVJ?
HCC70	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\qXGlEPTB;MT60OlA6PiEQvF2=	NWXuOGg{W0GQR1XS
no-10	Mlf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fGcWlEPTB;MT60OlE5OSEQvF2=	NXXuPY9VW0GQR1XS
JEG-3	NFTEW3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3i0W2lEPTB;MT61NFE{OiEQvF2=	M2jjOXNCVkeHUh?=
no-11	M{nzdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHRTWM2OD1zLkWwPFgzKM7:TR?=	M4XSUnNCVkeHUh?=
CHP-126	M1O4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHjnUoNKSzVyPUGuOVY3QTFizszN	NU\yclhLW0GQR1XS
EGI-1	MoLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV\JR\|UxRTFwNUiwNlUh\|ryP	MUPTRW5ITVJ?
D-392MG	NHiycGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPPTWM2OD1zLkW5OlMh\|ryP	NFvIVHBUSU6JRWK=
RT4	NFzyfHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoC1TWM2OD1zLkW5OlM4KM7:TR?=	NGXwTIlUSU6JRWK=
A204	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTFwNUm4NFEh\|ryP	MWHTRW5ITVJ?
NCI-H1304	M17ae2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrvbot3UUN3ME2xMlY{PTlzIN88US=>	NEK2U5VUSU6JRWK=
Becker	M3voW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHQTWM2OD1zLk[0NlQyKM7:TR?=	NGjVVplUSU6JRWK=
OE19	NF3wfIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4fqSmlEPTB;MT62OVUyQCEQvF2=	NEfac3pUSU6JRWK=
EKVX	NIPzRnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1ewV2lEPTB;MT62OVYyQCEQvF2=	M{nFT3NCVkeHUh?=
KLE	NHPXZplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYX5fmY2UUN3ME2xMlY2PzF2IN88US=>	NHXoXm1USU6JRWK=
K-562	Mn;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmLMTWM2OD1zLk[3NFM4KM7:TR?=	NVnR[nhsW0GQR1XS
MDA-MB-175-VII	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlvMTWM2OD1zLk[4PVk4KM7:TR?=	MnLQV2FPT0WU
NCI-H716	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PvU2lEPTB;MT62PVMxPCEQvF2=	MVLTRW5ITVJ?
Caov-3	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\wV2lEPTB;MT62PVQyOyEQvF2=	NWnSPIdSW0GQR1XS
HCC1187	M3P1XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NU\1PIRFUUN3ME2xMlcxPTR3IN88US=>	MV\TRW5ITVJ?
CAKI-1	M360OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHf0T3hKSzVyPUGuO\|IzQTJizszN	MYfTRW5ITVJ?
MOLT-16	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYXJR\|UxRTFwN{OzNFch\|ryP	MoX6V2FPT0WU
PC-3	Mmj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1[5TmlEPTB;MT63OVA5KM7:TR?=	M4DzNHNCVkeHUh?=
DV-90	MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\Oeo5KSzVyPUGuO\|U2QDVizszN	MXXTRW5ITVJ?
RXF393	NVi5VnpCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLpU2ZYUUN3ME2xMlc4Ojl2IN88US=>	MnvXV2FPT0WU
SK-NEP-1	MlvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV24eYFtUUN3ME2xMlgzOzN7IN88US=>	M4fITHNCVkeHUh?=
HCC1419	NHXLbpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXnJR\|UxRTFwOEK2PVIh\|ryP	MULTRW5ITVJ?
BV-173	M3zlc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;RPWlEPTB;MT64Nlk6PSEQvF2=	Mk\YV2FPT0WU
MKN7	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnOb2dzUUN3ME2xMlg6OjJizszN	M3PU[XNCVkeHUh?=
LAN-6	M17teWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nsRmlEPTB;MT64PVU2OyEQvF2=	MUjTRW5ITVJ?
Mo-T	M1nw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHKTWM2OD1zLkmwNFM6KM7:TR?=	M3HDRnNCVkeHUh?=
HCC1395	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTFwOUK4OlMh\|ryP	Mn\mV2FPT0WU
HC-1	M1mwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTFwOUO0O{DPxE1?	NUXoPJFJW0GQR1XS
HPAF-II	NGLlNlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NInqcZNKSzVyPUGuPVQ1OThizszN	M3q1[XNCVkeHUh?=
CPC-N	M17WdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWLlfo9lUUN3ME2xMlk5ODB{IN88US=>	NVfoPVdVW0GQR1XS
MKN45	M3vMe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXjN\|ZKSzVyPUGuPVkyOTlizszN	MoDoV2FPT0WU
NCI-H1693	NVn3U5R6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrPbVlKSzVyPUKuNFA1OzNizszN	MnLYV2FPT0WU
SHP-77	NYDZ[mJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTJwMEC1N\|Mh\|ryP	MlTlV2FPT0WU
NCI-H1522	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTJwMEG3NlQh\|ryP	MmG4V2FPT0WU
SW1573	NUfPUVF4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU\JR\|UxRTJwMEKyJO69VQ>?	MVnTRW5ITVJ?
DBTRG-05MG	Mlr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXe4dIh2UUN3ME2yMlA3ODh5IN88US=>	M3vGXHNCVkeHUh?=
SCC-4	MlLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlXxTWM2OD1{LkG0N\|Eh\|ryP	MXjTRW5ITVJ?
DMS-153	M1vmUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlPNTWM2OD1{LkG2OlY5KM7:TR?=	MUTTRW5ITVJ?
MDA-MB-415	NULxZ\|lUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTJwMUe1NkDPxE1?	NGrMbHVUSU6JRWK=
NCI-H2126	M4TMXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUP4PJRzUUN3ME2yMlIzQDh6IN88US=>	NY\lWms3W0GQR1XS
MDA-MB-453	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnPoTWM2OD1{LkKzN\|Ih\|ryP	NXHu[3c2W0GQR1XS
U-87-MG	NWrSXY9NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV7WPJhDUUN3ME2yMlI5PTl{IN88US=>	NULER3hMW0GQR1XS
LNCaP-Clone-FGC	NXT4PXVjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVPJR\|UxRTJwM{CxNFIh\|ryP	M3nyOHNCVkeHUh?=
NCI-H1581	NU\IdGZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLJTWM2OD1{LkOyNVA2KM7:TR?=	NV\aSW1wW0GQR1XS
BC-3	NIqx[WNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGfHbnFKSzVyPUKuN\|Y2ODlizszN	NYLvW2NzW0GQR1XS
HCC38	MkXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHntcJhKSzVyPUKuN\|g1PDdizszN	NHXISY9USU6JRWK=
HCC2218	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfPZpBKSzVyPUKuOFA5ODlizszN	NFjZXZdUSU6JRWK=
RO82-W-1	NY[yNppoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEfDeXdKSzVyPUKuOFEzPSEQvF2=	NHfuR5NUSU6JRWK=
C2BBe1	NHO0S3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX\V[ZYxUUN3ME2yMlQyPTd6IN88US=>	MkfXV2FPT0WU
LAMA-84	NYLyOnhuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXvXVcxUUN3ME2yMlU4OzZ6IN88US=>	M3TGNnNCVkeHUh?=
GMS-10	M1LHemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVnJR\|UxRTJwNUe2NVEh\|ryP	MkjyV2FPT0WU
GCT	M1jyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2W3SmlEPTB;Mj61PFY6PCEQvF2=	MYfTRW5ITVJ?
SK-CO-1	MmW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4TEeGlEPTB;Mj62NVY3KM7:TR?=	M1L3U3NCVkeHUh?=
NCI-H526	M2LIcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTJwNkO0OUDPxE1?	M1GzPXNCVkeHUh?=
SW1088	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWnJR\|UxRTJwN{e4N\|kh\|ryP	MkLjV2FPT0WU
HT55	MlX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTJwN{i2PVUh\|ryP	NFPacVlUSU6JRWK=
NB10	MnfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTJwOEG3OFgh\|ryP	MnjDV2FPT0WU
UACC-893	NFO1[3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTJwOEW3OFkh\|ryP	MoHjV2FPT0WU
NCI-H1618	MojaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXjzdZJwUUN3ME2yMlg5OTV\|IN88US=>	NXfkfIduW0GQR1XS
NCI-H1092	M3u2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M37BcWlEPTB;Mz6wO\|gyOiEQvF2=	NHq5fnVUSU6JRWK=
SBC-1	NInzcHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHPYNmZKSzVyPUOuNFg2PTNizszN	MkW3V2FPT0WU
NCI-H1623	NIjaNGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUjJR\|UxRTNwMEmzOEDPxE1?	NXXjVldzW0GQR1XS
SiHa	NYW5dIR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnzITWM2OD1\|LkGxPVc4KM7:TR?=	NVvYeIhJW0GQR1XS
D-263MG	NF;YOphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn\uTWM2OD1\|LkG0O\|g5KM7:TR?=	M3XF[3NCVkeHUh?=
NCI-H1573	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHLmSJlKSzVyPUOuNVk3PDFizszN	M{HwXHNCVkeHUh?=
NCI-H82	M33Fd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkHvTWM2OD1\|LkO0OFM6KM7:TR?=	NGPlcpZUSU6JRWK=
NCI-H2196	MlnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmPBTWM2OD1\|LkO1NFA5KM7:TR?=	NVjUcWN4W0GQR1XS
MFM-223	NGjIOnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3EVVBKSzVyPUOuN\|c{PTFizszN	NX3yfJRMW0GQR1XS
COLO-678	NXfJV5hRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFrvXIhKSzVyPUOuN\|gyQDZizszN	MlfvV2FPT0WU
EW-3	MonHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVnD[GhlUUN3ME2zMlQxQTVizszN	NFHpcoVUSU6JRWK=
MHH-NB-11	NXW1dIN5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlSxTWM2OD1\|LkS0NFY6KM7:TR?=	NUDsNJBrW0GQR1XS
EM-2	NVn1bJlRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MofmTWM2OD1\|Lk[zPVgh\|ryP	MkTWV2FPT0WU
FTC-133	M3;xeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYfiPYNwUUN3ME2zMlY2PDV6IN88US=>	MUXTRW5ITVJ?
NCI-H209	MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYj4PXQ2UUN3ME2zMlY4PjV\|IN88US=>	MXPTRW5ITVJ?
TGBC24TKB	MoDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7rd\|ZuUUN3ME2zMlY5OzV3IN88US=>	M3zuZXNCVkeHUh?=
LC-1F	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTNwN{G3OlQh\|ryP	M3i4SHNCVkeHUh?=
C-4-II	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlS5TWM2OD1\|Lke1OlQ{KM7:TR?=	NIfocFlUSU6JRWK=
NCI-H1650	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{Loe2lEPTB;Mz63PFQ2PSEQvF2=	M17jdnNCVkeHUh?=
JVM-2	NFPFZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYPJR\|UxRTNwOUO2N\|kh\|ryP	NUHOUpZoW0GQR1XS
CaR-1	M{H3dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MULJR\|UxRTNwOUe2NVch\|ryP	NIT6Nm9USU6JRWK=
MDA-MB-134-VI	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTRwMEK5OVIh\|ryP	MUXTRW5ITVJ?
NCI-H719	NYi0ToRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFS2VJhKSzVyPUSuNVU{QDhizszN	NHS1VXJUSU6JRWK=
GOTO	NYPrbmJjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTRwMkm3NFUh\|ryP	M1W3c3NCVkeHUh?=
NCI-N87	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkDPTWM2OD12LkO4PFIyKM7:TR?=	NGfLTWJUSU6JRWK=
NB6	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;FW2lEPTB;ND60NlUxQSEQvF2=	NWHyXGl5W0GQR1XS
DSH1	M1;5R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PB[2lEPTB;ND60O\|EyPiEQvF2=	MlrTV2FPT0WU
BT-20	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoP4TWM2OD12LkS5NFAzKM7:TR?=	M4\0O3NCVkeHUh?=
NCI-H1882	MljhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTRwNUC1O{DPxE1?	M4P5ZnNCVkeHUh?=
WM-115	NEewcpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX76[4J7UUN3ME20MlUxQDhzIN88US=>	M4rF[XNCVkeHUh?=
SKG-IIIa	MnzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEKzbohKSzVyPUSuOlc4PyEQvF2=	MXzTRW5ITVJ?
NCI-H69	NF3PRW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFXUWIJKSzVyPUSuO\|AzPzVizszN	MoXiV2FPT0WU
MSTO-211H	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjpc5NKSzVyPUSuPFM2PjVizszN	NHPiV2hUSU6JRWK=
Mewo	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1fi[WlEPTB;ND65OlMyOyEQvF2=	NWf5boVZW0GQR1XS
GI-ME-N	MnqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MljSTWM2OD13LkCwOVA6KM7:TR?=	M3jJdnNCVkeHUh?=
T98G	Ml\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGjOT2VKSzVyPUWuNFY2ODhizszN	MmXTV2FPT0WU
ECC4	M3\mXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEPlW5lKSzVyPUWuNFk{PzJizszN	NH\oeY9USU6JRWK=
EW-11	M2i2Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHtTYM6UUN3ME21MlE5ODl7IN88US=>	NYrBW29iW0GQR1XS
COLO-800	Mn2zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXLJR\|UxRTVwMUmzOFkh\|ryP	Mnr0V2FPT0WU
NCI-H1755	M3PLOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUjJR\|UxRTVwMkOwNlch\|ryP	MkHsV2FPT0WU
KMS-12-PE	NXntVm8yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2\ueWlEPTB;NT6zOVA5PSEQvF2=	MUHTRW5ITVJ?
HCC1954	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17CU2lEPTB;NT64OVk4OSEQvF2=	Mo\WV2FPT0WU
NCI-H187	MnzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHjlUVNKSzVyPUWuPVI6QDlizszN	MWLTRW5ITVJ?
LU-165	M4fROWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{O5dmlEPTB;NT65PVAxOiEQvF2=	MVvTRW5ITVJ?
YAPC	NID2WHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3rhXGlEPTB;NT65PVA3QCEQvF2=	MkHKV2FPT0WU
LU-139	NF3aSldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnnJTWM2OD14LkC4N\|Y5KM7:TR?=	M1jrenNCVkeHUh?=
D-502MG	M{Htcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mkf5TWM2OD14LkOyNFQ4KM7:TR?=	NGrsPVVUSU6JRWK=
IST-SL1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Ml\VTWM2OD14LkWzPVQ5KM7:TR?=	NUDkdYwxW0GQR1XS
DG-75	M{jqOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUD3TGFbUUN3ME22Mlg5Pzh4IN88US=>	M2jIWnNCVkeHUh?=
NCI-H1155	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUK3[JA4UUN3ME22Mlk2PThzIN88US=>	Mn3UV2FPT0WU
EFE-184	M2nKXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnznTWM2OD15LkOxOlk2KM7:TR?=	NUOxb5p4W0GQR1XS
AsPC-1	NYTkcXhCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3TKVmlEPTB;Nz60PFgxPyEQvF2=	NHjWSmNUSU6JRWK=
SW948	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIfK[lRKSzVyPUeuOVg{QTVizszN	MUXTRW5ITVJ?
NCI-H524	NGfMNmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTXNFN{UUN3ME25MlU5PjJ6IN88US=>	MV7TRW5ITVJ?
KOSC-2	NHnjellIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXkeZBPUUN3ME25MlYzQDN2IN88US=>	MVzTRW5ITVJ?
T-24	NGHZb5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUm0R3BbUUN3ME25Mlk1PDF3IN88US=>	MnTXV2FPT0WU
NCI-H748	MlH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIrZV45KSzVyPUGwMlY{QTdizszN	NFzrVopUSU6JRWK=
NCI-H23	NV:wbFJPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVXJR\|UxRTFyLk[0OFIh\|ryP	MYnTRW5ITVJ?
UACC-812	M4X6TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3zL[GlEPTB;MUGuO\|E4KM7:TR?=	MVjTRW5ITVJ?
SCLC-21H	M3m3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{LEUGlEPTB;MUKuNVU2OSEQvF2=	M1r1O3NCVkeHUh?=
NCI-SNU-16	NULzb5FTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYW4XWtvUUN3ME2xN{4yOjV6IN88US=>	NHPoTllUSU6JRWK=
HD-MY-Z	NUCxeYhuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3TMSGlEPTB;MUSuOlM3OyEQvF2=	MYLTRW5ITVJ?
SK-N-FI	NITDWoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofsTWM2OD1zND64PVEzKM7:TR?=	M3KzSXNCVkeHUh?=
LB647-SCLC	Mm\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGn0c5pKSzVyPUG1MlcyQTVizszN	M3rvO3NCVkeHUh?=
NCI-H345	M2XYfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVPJR\|UxRTF5LkO0N{DPxE1?	NIG3fodUSU6JRWK=
NCI-H1563	NXHubotmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXL1eYZSUUN3ME2xPE44PjBzIN88US=>	NW\QUo5jW0GQR1XS
RL	M2G4VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTJzLkK2OVYh\|ryP	NHTzOG5USU6JRWK=
KY821	M4\yU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4fHbWlEPTB;MkKuNFU2OyEQvF2=	NITafm5USU6JRWK=
JVM-3	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX3JR\|UxRTJ3LkC0NVMh\|ryP	Ml\kV2FPT0WU
NCI-H1793	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVLJR\|UxRTJ6LkW0PVkh\|ryP	MXPTRW5ITVJ?
LU-134-A	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2ixXWlEPTB;M{CuNlA{PyEQvF2=	MkC2V2FPT0WU
NCI-H1395	MnewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M13XPGlEPTB;M{KuNlQ{OSEQvF2=	Mn\vV2FPT0WU
NCI-H1993	M2rVNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvIRmNKSzVyPUOyMlgzOThizszN	MYDTRW5ITVJ?
P31-FUJ	M3qwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIrheHVKSzVyPUOzMlQ5QTlizszN	MXjTRW5ITVJ?
LS-513	MmnWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHflWHBKSzVyPUO1Mlg5PzlizszN	MXfTRW5ITVJ?
SK-MEL-1	NIHvNGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2Cwc2lEPTB;NECuN\|Q6QSEQvF2=	NH73dpBUSU6JRWK=
SW684	NGW1fXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH[5O5VKSzVyPUSzMlk3PjFizszN	NWHLOoNbW0GQR1XS
COR-L88	MoftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVXR[WtPUUN3ME20OE4xPjZ3IN88US=>	MV3TRW5ITVJ?
NCI-H889	NU\0enE{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTVTWM2OD12NT6wNFg4KM7:TR?=	M4H1d3NCVkeHUh?=
TALL-1	NHmzfpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4n4SWlEPTB;NE[uNVE6QSEQvF2=	MWnTRW5ITVJ?
KARPAS-299	M1TTZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkjmTWM2OD12Nz6xPVk{KM7:TR?=	NHW1VGdUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Cyclin D1 / p27 Kip1 ; PubMed: 28382170 Theranostics Western blotting showed that Obatoclax impacted cell cycle distribution through lowering cyclin D1 in K1 cells but in BCPAP cells, it impacted expression of p27 Kip1 rather than cyclin D1. p-Cyclin D1 ; PubMed: 28035994 Int J Mol Sci Cell line-dependent effect of obatoclax on cyclin D1 T286 phosphorylation. HCT116, HT-29, and LoVo cells were subject to 24 h-treatment with obatoclax (200 nM), followed by immunoblotting to evaluate the levels of threonine 286 (T286)-phosphorylated cyclin D1 (p-Cyclin D1) at indicated time points. α-Tubulin levels served as equal loading control; p-GSK3β / GSK3β / p-ERK / ERK / p-p38 / p38; PubMed: 28035994 Int J Mol Sci Obatoclax inhibits GSK3β but activates p38 (MAPK), while barely affecting ERK1/2 activity in HT-29 cells. HT-29 cells were exposed to 200 nM of obatoclax for 24 h. The status of activation of GSK3β, ERK1/2, and p38(MAPK) at indicated time points was determined by immunoblotting for corresponding phosphorylation. Specifically, serine 9-phosphorylation of GSK3β (p-GSK3β) reveals inhibition of GSK3β activity, whereas dual phosphorylation at threonine 202/tyrosine 204 of ERK1/2 (p-ERK1/2) and threonine 180/tyrosine 182 of p38 MAPK (p-p38) indicate activation of ERK1/2 and p38(MAPK), respectively. α-Tubulin levels served as equal loading control;	28382170 28035994
Growth inhibition assay	Cell proliferation ; PubMed: 28035994 Int J Mol Sci Obatoclax inhibits colorectal cancer cell proliferation. Human colorectal carcinoma cell lines HCT116, HT-29, and LoVo cells were treated with obatoclax (0, 50, 100, 200 nM) for 24, 48, and 72 h. The numbers of cells at each time point were counted using a Neubauer chamber. Data were presented as the percentage relative to the drug-untreated control. Cell viability; PubMed: 21368880 Cell Death Dis H727 NSCLC cells are resistant to obatoclax. H727 and H1975 NSCLC cells were treated with obatoclax at the indicated doses for 48 (left) or 72 h (right), and the viability of cells determined by ViaLight assay. The EC50 values of cells at 48 h were; H1975 267 nM; H727 3.2 μM. The EC50 values of cells at 72 h were; H1975 66 nM; H727 621 nM. Data are expressed as mean±S.D.	28035994 21368880

In vivo

Obatoclax also exhibits high antitumor activity in SCID mice bearing human C33A cerivical carcinoma tumors at a dose of 0.5 mg/kg. ^[1]

Protocol

Kinase Assay:^[1]	- Collapse Bcl-2 Binding affinity calculation: A predicted binding affinity for Obatoclax binding to BCL-2 is calculated using the SIE scoring function. ^[4] As a control in determining the reliability of the calculation, predicted binding affinities K_i) are calculated for a set of 12 small molecules with experimentally measured binding affinities to BCL-2.
Cell Research:^[2]	- Collapse Cell lines: Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) Concentrations: ~10 μM Incubation Time: 48-72 hours Method: Obatoclax is dissolved in DMSO at a stock concentration of 5 mM. Cell viability is assayed by MTT. Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) are seeded in 96-well plates at a density of 2 × 10⁴ per well for HMCLs or 5~10 × 10³ for PBLs. Various concentrations of Obatoclax are added to the cells, with or without IGF-1 (50 ng/mL) or IL-6 (10 ng/mL). Cells are incubated for 48-72 hours and cell viability is determined. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Female BALB/c or CB17 SCID/SCID mice bearing SW480, C33A, PC3, and 4T1 cells are used. Formulation: Obatoclax (tartrate salt) is formulated in 9.6% polyethylene glycol 300, 0.4% polysorbate 20, and 5% dextrose; while for the 4T1 tumor model, Obatoclax is formulated at a concentration of 0.6 mg/mL in 9.48% polyethylene glycol, 0.38% polysorbate 20, 1.2 m Dosages: 0.0313, 0.25, 0.5 and 2 mg/kg Administration: Administered intravenously (tail vein) once a day (Only for Reference)

References

[4] Naim M, et al. J Chem Inf Model, 2007, 47(1), 122-133.

- Collapse

Solubility (25°C)

In vitro	DMSO	83 mg/mL (200.73 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Obatoclax Mesylate (GX15-070) SDF

Molecular Weight	413.49
Formula	C₂₀H₁₉N₃O.CH₄O₃S
CAS No.	803712-79-0
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00438178	Completed	Drug: Obatoclax mesylate (GX15-070MS)	Hematological Malignancies	Gemin X\|Teva Pharmaceutical Industries	October 2005	Phase 1
NCT00600964	Completed	Drug: GX15-070MS	Chronic Lymphocytic Leukemia	Gemin X\|Teva Pharmaceutical Industries	September 2004	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Pan Bcl-2 Inhibitor

ABT-737 : Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.
Most Potent Bcl-2 Inhibitor

ABT-263 (Navitoclax) : Bcl-xL, K_i≤ 0.5 nM; Bcl-2, K_i≤ 1 nM; Bcl-w, K_i≤ 1 nM.
Newest Bcl-2 Family Activator

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.
Classic Bcl-2 Inhibitor

ABT-737 : BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

Related Bcl-2 Products

A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
Navitoclax (ABT-263)

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Venetoclax (ABT-199, GDC-0199)

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

Features:Re-engineered version of ABT-263 (Navitoclax).
ABT-737

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
UMI-77

UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.
TW-37

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Sabutoclax

Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
AT101

AT101, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Obatoclax Mesylate (GX15-070)

Cited by 70 Publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Obatoclax Mesylate (GX15-070) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Choose Your Country or Region

By Signaling Pathways

By product type

Obatoclax Mesylate (GX15-070)

Cited by 70 Publications

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Obatoclax Mesylate (GX15-070) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)